ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

EGFR Inhibitors for Neoadjuvant and Adjuvant Therapy of NSCLC

Journal: Archive of Organ Transplantation (Vol.1, No. 3)

Publication Date:

Authors : ;

Page : 078-079

Keywords : Non-small cell lung cancer; EGFR; Adjuvant; Neoadjuvant; Thoracic surgery;

Source : Downloadexternal Find it from : Google Scholarexternal

Abstract

5-year survival rates of Non-Small Cell Lung Cancer (NSCLC) remain unsatisfactory after surgery with curative intent and disease recurrences, including distant metastases, are frequent. Only a minority of this heterogeneous disease is positive for EGFR mutations and suitable for Tyrosine Kinase-Inhibitor biological agents, which however present limits in terms of stable response to treatment, due to the acquired drug resistances. A few trials administrating EGFR inhibitors combined with surgery, in neoadjuvant or adjuvant settings, have been reported with lack of evidence. The third-generation EGFR inhibitors, with the amelioration of techniques of gene profiling and the knowledge of pathways could extent the spectrum of complementary-to-surgery treatments in NSCLC at high risk of relapse.

Last modified: 2019-03-30 19:19:13